IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001193125-26-352201
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$75.49M | -$16.05M | -$27.73M | -$4.89M |
| EPS Diluted | -$12.31 | -$68.75 | -$0.64 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
